Methods of treating OX40 mediated recall immune responses using OX40L antibodies and agents useful for identifying same
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 8, 2013
Issued Date -
N/A
app pub date -
Dec 19, 2011
filing date -
Sep 11, 2002
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model of allergic asthma, inhibiting OX40/OX40L signaling during the secondary response to inhaled antigen suppressed lung inflammation. Inhibiting OX40 at the time of memory cell reactivation reduced the longevity of memory with further inflammation prevented upon tertiary encounter with antigen.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully